Cardiovascular benefits can increase Rybelsus’ competitiveness over other oral GLP-1RAs
The market for oral GLP-1RAs is expanding, and Rybelsus’ latest results showed its benefits in reducing the risk in cardiovascular…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Rybelsus
GLP1 agonists set to become the best-selling drugs in 2024: GlobalData
Shift could reflect a changing demand away from oncology toward addressing metabolic disorders